BeyondSpring Inc. (BYSI) AI Stock Analysis

BeyondSpring Inc. is a clinical-stage biopharmaceutical company headquartered in New York, New York, dedicated to developing novel cancer treatments. Founded in 2010, the company focuses on Plinabulin, a selective immune-modulating microtubule-binding agent. Plinabulin has completed Phase III trials for preventing chemotherapy-induced neutropenia and treating advanced non-small cell lung cancer (NSCLC). BeyondSpring also evaluates Plinabulin in combination with immuno-oncology therapies, such as nivolumab for NSCLC and nivolumab with ipilimumab for small cell lung cancer, as well as with radiation therapies. Additionally, it is advancing three preclinical small molecule immune agents and a drug development platform.

BeyondSpring's annual revenue rose from $180,000 in FY2020 to $1.4M in FY2021, remained at $1.4M in FY2022, and increased 29.6% to $1.8M in FY2023, representing a three-year revenue CAGR of 113.5%. Gross margin shifted from 100.0% in FY2022 to -17.2% in FY2023, while operating margin improved from -2756.4% to -861.3%. Net losses contracted from -$61.0M in FY2020 and -$64.2M in FY2021 to -$21.0M in FY2023 as R&D spending decreased from $41.8M to $7.3M. In the trailing twelve months through June 30, 2026, revenue totaled $1.9M, supported by 14.3% quarterly year-over-year revenue growth.

As of June 30, 2026, BeyondSpring held $6.5M in cash and short-term investments against total debt of $171,000, resulting in net cash of $6.4M. Total assets were $14.6M, while shareholders' equity was -$35.6M, reflecting negative equity alongside a current ratio of 0.70. Free cash flow was -$16.6M in FY2023, compared to -$50.1M in FY2021. For FY2025, capital expenditures were $50,000, and the company's share count increased 5.4% over five years.

BeyondSpring trades at an enterprise value of $23.5M and a forward P/E of 10.5x, below the US-listed Healthcare median of 17.3x. However, its price-to-sales ratio of 46.0x and EV-to-revenue multiple of 41.8x sit well above the US-listed Healthcare median price-to-sales multiple of 4.1x. Its price-to-book multiple is 5.4x. Over the past year, the stock fell 68.7%, underperforming the 16.8% gain for the S&P 500 (SPY), while its five-year return of -96.6% lagged the index return of 83.0%.

Wall Street analysts have set a mean price target of $1.25 for BeyondSpring, representing an implied upside of 123.6% from its last closing price of $0.56 on October 16, 2026. The company achieved 0 EPS beats over the last 4 quarters. BeyondSpring is scheduled to report its next earnings results on November 11, 2026.

This page is an AI-written research summary of BeyondSpring Inc. (BYSI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BYSI income statement, BYSI balance sheet, BYSI key metrics, BYSI chart. See the BYSI stock overview for the latest quote and news.